Psy36 European Economic Evaluation of Oros® Hydromorphone in the Management of Severe Chronic Cancer and Non-Cancer Pain

Hauber, AB; Lam, Andrew C L; Fleischmann, Jochen; Wilson, Rachel

doi:10.1016/s1098-3015(10)67086-6

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacoeconomic data concerning the use of OROS Ò hydromorphone in patients with chronic pain are available from three studies, [53][54][55] two of which are available as abstracts and posters. [54,55] Pharmacoeconomic analyses of OROS Ò hydromorphone, in common with all pharmacoeconomic analyses, are subject to a number of limitations.…”

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

“…[54] This study utilized a decision-analytic cost-utility model to investigate the cost-effectiveness of OROS Ò hydromorphone compared with morphine sustained release (SR), oxycodone CR, and twice-daily hydromorphone over a 1-year time horizon; because oxycodone CR is not available in Portugal, and twice-daily hydromorphone is not available in Portugal or Italy, these opioids were not considered in the analyses of these countries. [54] This study utilized a decision-analytic cost-utility model to investigate the cost-effectiveness of OROS Ò hydromorphone compared with morphine sustained release (SR), oxycodone CR, and twice-daily hydromorphone over a 1-year time horizon; because oxycodone CR is not available in Portugal, and twice-daily hydromorphone is not available in Portugal or Italy, these opioids were not considered in the analyses of these countries.…”

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

See 1 more Smart Citation

OROS® Hydromorphone Prolonged Release

Carter

Keating

2010

CNS Drugs

View full text Add to dashboard Cite

OROS hydromorphone prolonged release (OROS hydromorphone) [Jurnista] is a once-daily formulation of the opioid agonist hydromorphone that utilizes OROS (osmotic-controlled release oral delivery system) technology to deliver the drug at a near constant rate, thereby providing consistent analgesia over a 24-hour period. It is indicated for use in patients with severe pain and contraindicated in those with acute or post-operative pain. In several, randomized, multicentre, phase III trials, oral OROS hydromorphone administered once daily for up to 52 weeks was generally effective in the treatment of patients with chronic, moderate to severe cancer or nonmalignant/noncancer pain with regard to improvements from baseline to endpoint in patient-assessed measures of pain intensity, pain relief and/or functional impairment. Pharmacoeconomic analyses suggest that OROS hydromorphone provides greater cost utility than other opioids in this patient population. In addition, OROS hydromorphone was generally well tolerated in clinical trials, with most adverse events being mild to moderate in severity and similar to those seen with other opioids. Thus, OROS hydromorphone is an effective and useful alternative to other opioids for the treatment of patients with severe pain.

show abstract